tiprankstipranks
Trending News
More News >
Relmada Therapeutics Inc (RLMD)
NASDAQ:RLMD
US Market

Relmada Therapeutics (RLMD) Technical Analysis

Compare
401 Followers

Technical Sentiment

Overall Consensus
Strong Buy
14Bullish
6Neutral
2Bearish
Technical Analysis Consensus
Buy
3Bullish
6Neutral
1Bearish
Moving Average Consensus
Strong Buy
11Bullish
0Neutral
1Bearish
Relmada Therapeutics Inc’s (RLMD) Moving Averages Convergence Divergence (MACD) indicator is 0.12, suggesting Relmada Therapeutics Inc is a Buy.
Relmada Therapeutics Inc’s (RLMD) 20-Day exponential moving average is 4.32, while Relmada Therapeutics Inc’s (RLMD) share price is $2.26, making it a Buy.
Relmada Therapeutics Inc’s (RLMD) 50-Day exponential moving average is 3.84, while Relmada Therapeutics Inc’s (RLMD) share price is $2.26, making it a Buy.

Relmada Therapeutics (RLMD) Pivot Points

Jan 10, 2026, 03:47 PM
Name
S3
S2
S1
Pivot Points
R1
R2
R3
Classic
3.83
3.94
4.13
4.24
4.43
4.54
4.73
Fibonacci
3.94
4.05
4.13
4.24
4.35
4.43
4.54
Pivot points are a technical analysis tool used by traders to identify potential support and resistance levels in financial markets. Pivot points are calculated based on the previous day's high, low, and close prices, and are used to help traders identify levels at which the price may reverse or continue to trend.

Relmada Therapeutics (RLMD) Moving Averages

Jan 10, 2026, 03:47 PM
Period
Simple
Exponential
MA5
4.29Buy
4.35Buy
MA10
4.44Sell
4.37Buy
MA20
4.37Buy
4.32Buy
MA50
3.90Buy
3.84Buy
MA100
2.77Buy
3.05Buy
MA200
1.65Buy
2.02Buy
Relmada Therapeutics Inc’s (RLMD) 10-Day exponential moving average is 4.37, while Relmada Therapeutics Inc’s (RLMD) share price is $2.26, making it a Buy.
Relmada Therapeutics Inc’s (RLMD) 100-Day exponential moving average is 3.05, while Relmada Therapeutics Inc’s (RLMD) share price is $2.26, making it a Buy.
Relmada Therapeutics Inc’s (RLMD) stock price is $2.26 and Relmada Therapeutics Inc’s (RLMD) 50-day simple moving average is 3.90, creating a Buy signal.
Relmada Therapeutics Inc’s (RLMD) stock price is $2.26 and Relmada Therapeutics Inc’s (RLMD) 100-day simple moving average is 2.77, creating a Buy signal.
Relmada Therapeutics Inc’s (RLMD) stock price is $2.26 and Relmada Therapeutics Inc’s (RLMD) 200-day simple moving average is 1.65, creating a Buy signal.

Relmada Therapeutics (RLMD) Technical Indicators

Jan 10, 2026, 03:47 PM
Name
Value
Implied Action
RSI (14)
54.36
Neutral
STOCH (9,6)
29.40
Neutral
STOCHRSI (14)
29.40
Neutral
MACD (12,26)
0.12
Buy
ADX (14)
24.40
Neutral
Williams %R
-55.40
Buy
CCI (14)
-2.58
Neutral
ATR (14)
0.39
-
Ultimate Oscillator
54.23
Neutral
ROC
10.47
Buy
Relmada Therapeutics Inc’s (RLMD) Relative Strength Index (RSI) is 54.36, creating a Neutral signal.
Relmada Therapeutics Inc’s (RLMD) Trend Strength Indicator (ADX) is 24.40, creating a Neutral signal.
Relmada Therapeutics Inc’s (RLMD) Commodity Channel Index (CCI) is -2.58, creating a Neutral signal.
Relmada Therapeutics Inc’s (RLMD) Price Rate of Change (ROC) is 10.47, creating a Buy signal.

FAQ

Is RLMD a Buy, Hold, or Sell?
Based on RLMD’s technical indicators, RLMD is a Strong Buy.
    What is RLMD’s RSI (14)?
    RLMD’s RSI (14) is 54.36, which suggests RLMD is a Neutral.
      What is RLMD’s MACD?
      RLMD’s MACD is 0.12, which suggests RLMD is a Buy.
        What is RLMD’s 5-day moving average?
        RLMD’s 5-day moving average is 4.29, which suggests RLMD is a Buy.
          What is RLMD’s 20-day moving average?
          RLMD 20-day moving average is 4.37, which suggests RLMD is a Buy.
            What is RLMD’s 50-day moving average?
            RLMD’s 50-day moving average is 3.90, which suggests RLMD is a Buy.
              What is RLMD’s 200-day moving average?
              RLMD’s 200-day moving average is 1.65, which suggests RLMD is a Buy.
                What is RLMD’s Williams % R (14)?
                RLMD’s Williams % R (14) is -55.40, which suggests RLMD is a Buy.
                  What is RLMD’s CCI (14)?
                  RLMD’s CCI (14) is -2.58, which suggests RLMD is a Neutral.